| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | Regulatoriskt partnerskap
> Arbeta med tillsynsmyndigheter | 5 000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Regulatoriskt partnerskap
> Arbeta med tillsynsmyndigheter | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Andning
> Lungfibros | Regulatoriskt partnerskap
> Arbeta med tillsynsmyndigheter | 1 000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Neuromuskulär
> Duchenne | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | 5 000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Patientförespråkande
> Patienträttigheter | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | 10 000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Reumatisk
> Lupus | Regulatoriskt partnerskap
> Delta i utvärderingar av medicinsk teknik (HTA) och ersättningsgranskningar | 100 000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Patientförespråkande
> Patienträttigheter | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Blödning
> Blödningsrubbningar: de flesta typer | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 5 000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Äldre personer
> Äldre personer | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sällsynt
> Sällsynta sjukdomar: metaboliska/lysosomala | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 100 000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Reumatisk
> Reumatiska sjukdomar: de flesta typer | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 10 000 | National | Regularly | 119062924366 |
| Ministry of Health. | Kardiovaskulär
> Hjärt- & kärlsjukdomar | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 5 000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Andning
> Lungfibros | Regulatoriskt partnerskap
> Delta i/facilitera möten med beslutsfattare/tillsynsmyndigheter | 1 000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Kardiovaskulär
> Hjärt- & kärlsjukdomar | Regulatoriskt partnerskap
> Med andra hälso- och sjukvårdsförespråkare | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Gastrointestinal
> Gastrointestinal: övrigt | Regulatoriskt partnerskap
> Med andra hälso- och sjukvårdsförespråkare | 1 000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Sällsynt
> Wilsons sjukdom | Regulatoriskt partnerskap
> Med andra hälso- och sjukvårdsförespråkare | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 1 000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Patientsäkerhet
> Iatrogen | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 1 000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Celiaki | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 100 000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Lever
> Leversjukdomar: transplantationer | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 5 000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Andning
> Lungfibros | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 1 000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Sällsynt
> Sällsynta sjukdomar: de flesta typer | Påverka politik och lagstiftning
> Påverka hälso- och sjukvårdspolitik och lagstiftning | 100 000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Blödning
> Blödningsrubbningar: de flesta typer | Påverka politik och lagstiftning
> Delta i offentliga utfrågningar och samråd | 5 000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniska sjukdomar i allmänhet | Påverka politik och lagstiftning
> Delta i offentliga utfrågningar och samråd | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Celiaki | Påverka politik och lagstiftning
> Delta i offentliga utfrågningar och samråd | 100 000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Neurologisk
> Multipel skleros | Påverka politik och lagstiftning
> Delta i offentliga utfrågningar och samråd | 5 000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Celiaki | Påverka politik och lagstiftning
> Mobilisera parlamentariker och politiska ledare | 100 000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Påverka politik och lagstiftning
> Mobilisera parlamentariker och politiska ledare | 5 000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverka politik och lagstiftning
> Mobilisera parlamentariker och politiska ledare | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverka politik och lagstiftning
> Förespråka lagstiftning och rättigheter för patientskydd | 1 000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Celiaki | Påverka politik och lagstiftning
> Bidra till utformningen av folkhälsolagstiftning | 100 000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Cancer
> Cancer: pankreas | Påverka politik och lagstiftning
> Hantera hinder/avvikelser inom medicinsk vård | 1 000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverkansarbete för prissättning och prisvärdhet
> Förespråka rättvisa läkemedelspriser | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Andning
> KOL | Påverkansarbete för prissättning och prisvärdhet
> Förespråka rättvisa läkemedelspriser | 1 000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniska sjukdomar i allmänhet | Påverkansarbete för prissättning och prisvärdhet
> Delta i förhandlingar med prisgranskningsnämnden | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sällsynt
> Sällsynta sjukdomar: genetiska | Påverkansarbete för prissättning och prisvärdhet
> Delta i förhandlingar med prisgranskningsnämnden | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sällsynt
> Sällsynta sjukdomar: metaboliska/lysosomala | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Andning
> Andning: de flesta tillstånd | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 5 000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Andning
> KOL | Påverkansarbete för prissättning och prisvärdhet
> Förespråkar inkludering av produkten i ersättningslistor/nationella läkemedelsförteckningar | 1 000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Cancer
> Cancer: pankreas | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 1 000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Patientförespråkande
> Patienträttigheter | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Endokrin
> Diabetes (både typ 1 och typ 2) | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 5 000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Ben
> Artros och osteoporos | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 5 000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniska sjukdomar i allmänhet | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Andning
> KOL | Förbättra åtkomstvägar
> Underlätta rättvis tillgång till läkemedel/hälso- och sjukvård | 1 000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Sällsynt
> Sällsynta sjukdomar: de flesta typer | Evidensbaserat patientinput
> Använd patientinsikter för att informera beslut | 1 000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Evidensbaserat patientinput
> Använd patientinsikter för att informera beslut | 10 000 | National | Sometimes | 119073823192 |
| They consult us. | Neurologisk
> Fibromyalgi | Evidensbaserat patientinput
> Använd patientinsikter för att informera beslut | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Sällsynt
> Sällsynta sjukdomar: de flesta typer | Evidensbaserat patientinput
> Tillhandahåll verkliga bevis (RWE) till tillsynsmyndigheter | 1 000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Sällsynt
> Sällsynta sjukdomar: de flesta typer | Evidensbaserat patientinput
> Utnyttja patientberättelser och narrativ från levd erfarenhet | 1 000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Neurodegenerativ
> Alzheimers | Evidensbaserat patientinput
> Utnyttja patientberättelser och narrativ från levd erfarenhet | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniska sjukdomar i allmänhet | Evidensbaserat patientinput
> Omvandla bevis och insikter till policyunderlag | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Äldre personer
> Äldre personer | Diagnos och läkemedelsleverans
> Säkerställ säker och effektiv läkemedelsanvändning | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Sällsynt
> Von Hippel-Lindaus syndrom | Diagnos och läkemedelsleverans
> Säkerställ säker och effektiv läkemedelsanvändning | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Diagnos och läkemedelsleverans
> Säkerställ säker och effektiv läkemedelsanvändning | 10 000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Äldre personer
> Äldre personer | Diagnos och läkemedelsleverans
> Delta i utvecklingen av kliniska riktlinjer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Äldre personer
> Äldre personer | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Blödning
> Hemofili | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Kardiovaskulär
> Hjärt- & kärlsjukdomar | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Sällsynt
> Sällsynta sjukdomar: de flesta typer | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 1 000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Neurologisk
> Multipel skleros | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 5 000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Neurologisk
> Multipel skleros | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 10 000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 10 000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 5 000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientförespråkande
> Patienträttigheter | Institutionell styrning
> Se till att det finns representation inom statliga rådgivande organ | 10 000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Neurologisk
> Neurologiska: de flesta tillstånd | Institutionell styrning
> Upprätthåll formell status som allmännyttig eller välgörenhetsorganisation | 1 000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | Institutionell styrning
> Upprätthåll formell status som allmännyttig eller välgörenhetsorganisation | 5 000 | Local | Regularly | 119072832940 |
interaktioner
åtgärder & påverkansarbete
19 omnämnanden
